{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T15:00:27Z","timestamp":1788102027869,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.diagmicrobio.2017.06.023","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T23:47:23Z","timestamp":1498866443000},"page":"168-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci"],"prefix":"10.1016","volume":"89","author":[{"given":"Francis F.","family":"Arhin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Lalonde","family":"Seguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Belley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Moeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jgar.2017.03.002","article-title":"Agar dilution minimum inhibitory concentrations (MICs) underrepresent oritavancin in vitro activity against staphylococci and enterococci","volume":"9","author":"Arhin","year":"2017","journal-title":"J Glob Antimicrob Res"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jgar.2017.01.003","article-title":"Assessment of the potential for oritavancin MIC changes among Staphylococcus aureus nasal carriage isolates following systemic oritavancin treatment in a phase 2 study in patients with acute bacterial skin and skin-structure infections","volume":"9","author":"Arhin","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0015","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1128\/AAC.01513-07","article-title":"Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing","volume":"52","author":"Arhin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1586\/14787210.2014.870886","article-title":"Antibiotic resistance in Enterococcus faecium clinical isolates","volume":"12","author":"Cattoir","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0025","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Document M7-A10","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0030","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ijantimicag.2016.07.019","article-title":"Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus","volume":"48","author":"Corey","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0035","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1128\/AAC.42.5.1303","article-title":"Historical yearly usage of vancomycin","volume":"42","author":"Kirst","year":"1998","journal-title":"Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0040","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1128\/AAC.00742-09","article-title":"Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies","volume":"53","author":"Kosowska-Shick","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0045","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1128\/AAC.44.11.3017-3021.2000","article-title":"Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis","volume":"44","author":"Lefort","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0050","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1093\/jac\/dkw319","article-title":"Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency","volume":"71","author":"Mendes","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0055","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.idc.2016.02.006","article-title":"2016. Vancomycin- resistant enterococci: therapeutic challenges in the 21st century","volume":"30","author":"Miller","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0060","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.clinthera.2015.04.008","article-title":"Clinical outcomes of Daptomycin for vancomycin-resistant enterococcus bacteremia","volume":"37","author":"Moise","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0065","series-title":"Manual of clinical microbiology","author":"Murray","year":"2007"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0070","first-page":"217","article-title":"Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management","volume":"8","author":"O'Driscoll","year":"2015","journal-title":"Infec Drug Resist"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0075","series-title":"Prescribing information, January 2016 ed","article-title":"OrbactivR (oritavancin) For injection, for intravenous use","year":"2016"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0080","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1128\/AAC.00207-11","article-title":"Genetic basis for daptomycin resistance in enterococci","volume":"55","author":"Palmer","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0085","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/cid\/ciw173","article-title":"Influence of minimum inhibitory concentration in clinical outcomes of Enterococcus faecium bacteremia treated with Daptomycin: is it time to change the breakpoint?","volume":"62","author":"Shukla","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0090","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dkw229","article-title":"Sequential steps of daptomycin resistance in Enterococcus faecium and reversion to hypersusceptibility through IS-mediated inactivation of the lia FSR operon","volume":"71","author":"Sinel","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0095","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/jac\/dkw451","article-title":"Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci","volume":"72","author":"Sweeney","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.06.023_bb0100","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1128\/AAC.00714-13","article-title":"Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections","volume":"57","author":"Whang","year":"2013","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317302146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317302146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T23:54:16Z","timestamp":1569628456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889317302146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0732889317302146"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.06.023","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}